No to CF drug Orkambi at cost of €391 million over five years
Funding denied despite CF sufferers pleas for access
The state’s drug assessment watchdog has recommended against funding the cystic fibrosis drug Orkambi – to which Irish CF sufferers have pleaded for access.
The National Centre for Pharmacoeconomics (NCPE) carried out a cost-effectiveness assessment of the drug, which is manufactured by Vertex Pharmaceuticals.
The NCPE said 505 patients with Cystic Fibrosis would be potential candidates. It estimated that the five year budget impact to the HSE would be €391 million over five ...
